Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Complications of Bacillus Calmette-Guerin Immunotherapy in 1,278 Patients with Bladder Cancer

Abstract

Our series of 195 patients, plus 134 reported on in the literature and 949 reviewed by various physicians provide 1,278 patients for review of bacillus Calmette-Guerin therapy complications. Cystitis occurred in 91 per cent of the patients. Complications identified included fever more than 103F in 50 patients (3.9 per cent), granulomatous prostatitis in 17 (1.3 per cent), bacillus Calmette-Guerin pneumonitis or hepatitis in 12 (0.9 per cent), arthritis or arthralgia in 6 (0.5 per cent), hematuria requiring catheterization or transfusion in 6 (0.5 per cent), skin rash in 5 (0.4 per cent), skin abscess in 5 (0.4 per cent), ureteral obstruction in 4 (0.3 per cent), epididymo-orchitis in 2 (0.2 per cent), bladder contracture in 2 (0.2 per cent), hypotension in 1 (0.1 per cent) and cytopenia in 1 (0.1 per cent). Most of the severe irritative side effects and subsequent systemic complications can be prevented with prophylactic isoniazid given for 3 days, beginning the morning of treatment. Patients with life-threatening systemic bacillus Calmette-Guerin infection or anaphylaxis should receive 500 mg. cycloserine twice daily for 3 days in addition to combination antituberculous therapy because the rapid action of this drug may be life-saving. Direct intralesional bacillus Calmette-Guerin immunotherapy can produce sepsis and death, and should be avoided but intravesical bacillus Calmette-Guerin generally is well tolerated and has produced no complication in more than 95 per cent of the patients treated.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0022-5347(17)45606-0

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 10 references

Research works printed but not linked: 3

  1. Zincke, 1984, Tumor recurrence after intravesical instillation of thio-tepa (TT) and mitomycin C (MC) at time of transurethral resection of bladder cancer (TaTcis) and postoperatively, J. Urol., 131, 138A
  2. Stober, 1980, BCG Immunotherapy zur Rezidivprophylaxe beim har Blasenkarzinom, Therapiewoch, 30, 6067
  3. Flamm, 1981, Adjuvante lokale Immunotherapie mit bacillus Calmette-Guerin (BCG) in der Behandlung des Urothelkarzinoms der Harnblase, Wien. Med. Wochenschr., 131, 501

Cited by

See all 394

Metadata

Authors
Lamm, D. L., Stogdill, V. D., Stogdill, B. J., & Crispen, R. G.
Venue
Journal of Urology
Published
1986-02
Volume
135
Issue
2
Pages
272-274
ISSN
  • 0022-5347 (ISSN-L)
  • 1527-3792
OpenAlex
W2414380551
Cited by
394
References
10
Citations by year
2026: 5 · 2025: 3 · 2024: 4 · 2023: 6 · 2022: 4 · 2021: 6 · 2020: 8 · 2019: 4 · 2018: 9 · 2017: 5 · 2016: 4 · 2015: 17 · 2014: 7 · 2013: 7 · 2012: 10
FWCI
29.16
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Journal of Urology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
  • Health Sciences › Medicine › Urology › Urinary Tract Infections Management
  • Health Sciences › Medicine › Urology › Urinary Bladder and Prostate Research
Keywords
BCG vaccine, BCG immunotherapy, bladder cancer, treatment complications, cystitis, fever, granulomatous prostatitis, pneumonitis, hepatitis, isoniazid preventive therapy, cycloserine, anaphylaxis, sepsis, hematuria, epididymo-orchitis
MeSH terms
Biological Products, Urinary Bladder Neoplasms, Combined Modality Therapy, Cycloserine, Female, Humans, Immunotherapy, Isoniazid, Male, Mycobacterium bovis, Time Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Complications of Bacillus Calmette-Guerin Immunotherapy in 1,278 Patients with Bladder Cancer. https://app.cochat.ai/papers/10.1016/s0022-5347(17)45606-0
The paper
Lamm, D. L., Stogdill, V. D., Stogdill, B. J., & Crispen, R. G. (1986). Complications of Bacillus Calmette-Guerin Immunotherapy in 1,278 Patients with Bladder Cancer. Journal of Urology. https://doi.org/10.1016/s0022-5347(17)45606-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.